Suneva Medical is described as a leader in regenerative aesthetics. The company focuses on developing, manufacturing and commercializing branded products for providers and their patients. It is a privately held aesthetics company. Suneva completed a $15 million capital raise, as reported. The company is based in San Diego, CA. Suneva Medical is an innovative aesthetics company based in San Diego that develops, manufactures and commercializes differentiated products for the general dermatology and aesthetic markets. It currently offers Bellafill, an FDA‑approved dermal filler for treatment of nasolabial folds and facial acne scars, and the Regenica skin care line designed to enhance skin’s natural repair and renewal mechanisms. The company is led by Chairman and CEO Nicholas L. Teti, Jr. The financing aims to strengthen Suneva Medical’s revenue growth and further support ongoing commercialization of its flagship products. Major equity shareholders include HealthCare Royalty Partners, Almirall, S.A. and Polaris Partners. Suneva Medical is a San Diego, CA–based aesthetics company that markets Bellafill, an FDA-approved dermal filler for the correction of moderate to severe atrophic, distensible facial acne scars on the cheek in patients over 21. The company is led by Chairman and CEO Nicholas L. Teti, Jr. Suneva is actively commercializing Bellafill and using financing to support the ongoing launch of the product. Recently it closed a $15M equity investment, completed a $20.4M growth-capital term loan, and expanded its working capital facility with Comerica Bank, strengthening near-term liquidity. Bellafill is the company's primary commercial asset and the focus of its sales and marketing efforts. Suneva Medical develops, manufactures and commercializes novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets ArteFill in the US, Korea and Singapore; ReFissa and Regenica Skincare in the U.S.; and Bellafill in Canada. Led by Chairman and CEO Nicholas L. Teti, Jr., Suneva focuses on product development and commercialization within aesthetic medicine. The company recently raised new capital to support growth and working capital needs. The financing package includes equity and debt components and milestone-linked investments intended to advance product-related objectives. No revenue or user metrics were disclosed in the article.

Total raised

$130M

Funding rounds

6

Latest round

Equity

Latest activity

Sep 2021